A 65-year-old man underwent an abdominal ultrasound of acute abdominal pain, showing an incidental. Subsequently, a magnetic resonance imaging (MRI) scan of the abdomen revealed additional liver lesions, hyper-intense on T2-weighted images. Needle biopsy of the largest lesion showed a well-differentiated neuroendocrine tumor (NET) of gastrointestinal origin. The patient underwent a whole-body positron emission tomography--computed tomography (PET/CT) scan using ^68^Ga-DOTATATE (somatostatin \[SST\]-analog) for accurate disease staging, which showed approximately 16 tracer-avid liver lesions. The hottest lesion (SUVmax: 52.4) was inferior to the medial segment of the left lobe ([Fig. 1A](#F1){ref-type="fig"}: red arrow) corresponding to the largest lesion seen on MRI ([Fig. 1B](#F1){ref-type="fig"}: arrow). A prominent tracer-avid lesion (SUVmax: 72.8) was seen in the terminal ileum/ileocecal junction ([Fig. 1A](#F1){ref-type="fig"}: black arrow; [Fig. 1C](#F1){ref-type="fig"}, [D](#F1){ref-type="fig"}: white arrows) strongly suggesting the location of the primary tumor. In addition, two ^68^Ga-DOTATATE-positive mesenteric lymph nodes were seen in the abdomen and left inferior pelvis ([Fig. 1A](#F1){ref-type="fig"}: green arrows; SUVmax: 62.3 & 25.4, respectively) ([Fig. 1D](#F1){ref-type="fig"}: yellow arrow). The patient underwent exploratory laparotomy with radio-guided (using a gamma probe post ^68^Ga-DOTATATE injection) excision of the tumors from the small bowel, the mesenteric lymph nodes and the liver lesions. Subsequently pathological evaluation of all excised specimens revealed primary grade-I NET in the terminal ileum with metastases to the liver and mesenteric lymph nodes.

![(A) Whole-body maximum intensity projection (MIP)Β 68Ga-DOTATATE positron emission tomography (PET) image. (B) Axial T2-weighted magnetic resonance image of the upper abdomen. (C) Axial fused ^68^Ga-DOTATATE PET/CT image of the pelvis. (D) Coronal-fused ^68^Ga-DOTATATE PET/CT image of the abdomen and pelvis](AnnGastroenterol-30-130-g001){#F1}

Since the majority of NETs overexpress SST receptors, they can be effectively targeted and localized using radiolabeled SST analogs \[[@ref1],[@ref2]\]. In the presented case 68Ga-DOTATATE PET/CT accurately showed the extent of the disease and confidently revealed the location of the primary tumor, demonstrating the utility of PET/CT using ^68^Ga-DOTA-conjugated peptides in the accurate management of patients with gastro-entero-pancreatic NETs \[[@ref3]\].
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